New urinary biomarkers for diabetic kidney disease

Biomarker Research

Volumn 1, Issue 1, 2013, Pages

  Wang, Cheng ^a   Li, CuiCui ^a   Gong, WenYu ^a   Lou, Tanqi ^a  

^a THE THIRD AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

Author keywords

Biomarker; Diabetic kidney disease; Urine

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; ALBUMIN; ALPHA 1 MICROGLOBULIN; ALPHA ACTIN 4; ALPHA1 GLYCOPROTEIN; ALPHA2 GLYCOPROTEIN; BIOLOGICAL MARKER; CERULOPLASMIN; COLLAGEN TYPE 4; CREATININE; CYSTANIC C; GELATINASE B; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G2; IMMUNOGLOBULIN G4; IMMUNOGLOBULIN M; MONOCYTE CHEMOTACTIC PROTEIN 1; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; PODOCALYXIN; PODOCIN; SYNAPTOPODIN; TRANSFERRIN; UNCLASSIFIED DRUG;

CLINICAL PRACTICE; DIABETIC NEPHROPATHY; DISEASE ASSOCIATION; DISEASE COURSE; END STAGE RENAL DISEASE; FOLLOW UP; GEL ELECTROPHORESIS; GLOMERULONEPHRITIS; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY INJURY; MASS SPECTROMETRY; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PODOCYTE; PRIORITY JOURNAL; PROTEOMICS; REVIEW; SENSITIVITY AND SPECIFICITY; URINALYSIS;

EID: 85043557933     PISSN: None     EISSN: 20507771     Source Type: Journal    
DOI: 10.1186/2050-7771-1-9     Document Type: Review

References (36)

1. International Diabetes Federation Diabetes Atlas Fifth Edition, International Diabets Federation 2011, Belgium: Brussels, International Diabetes Federation.
2. Zhou Y, Zhang X, Wu J. Clinical significance of microtransferrinuria in diabetic patients. Zhonghua nei ke za zhi 1997, 36:165-168.
3. Hellemons ME, Kerschbaum J, Bakker SJ, et al. Validity of biomarkers predicting onset or progression of nephropathy in patients with Type 2 diabetes: a systematic review. Diabet Med 2012, 29:567-577.
4. Mackinnon B, Shakerdi L, Deighan CJ, et al. Urinary transferrin, high molecular weight proteinuria and the progression of renal disease. Clin Nephrol 2003, 59:252-258.
5. Narita T, Hosoba M, Kakei M, et al. Increased urinary excretions of immunoglobulin G, ceruloplasmin, and transferrin predict development of microalbuminuria in patients with type 2 diabetes. Diabetes Care 2006, 29:142-144. 10.2337/diacare.29.01.06.dc05-1063, 16373913.
6. Bangstad HJ, Kofoed-Enevoldsen A, Dahl-Jorgensen K, et al. Glomerular charge selectivity and the influence of improved blood glucose control in Type 1 (insulin-dependent) diabetic patients with microalbuminuria. Diabetologia 1992, 35:1165-1169. 10.1007/BF00401371, 1478369.
7. Gohda T, Walker WH, Wolkow P, et al. Elevated urinary excretion of immunoglobulins in nonproteinuric patients with type 1 diabetes. Am J Physiol Renal Physiol 2012, 303:F157-F162. 10.1152/ajprenal.00443.2011, 22513848.
8. Bakoush O, Tencer J, Tapia J, et al. Higher urinary IgM excretion in type 2 diabetic nephropathy compared to type 1 diabetic nephropathy. Kidney Int 2002, 61:203-208. 10.1046/j.1523-1755.2002.00108.x, 11786102.
9. Tofik R, Torffvit O, Rippe B, Bakoush O. Increased urine IgM excretion predicts cardiovascular events in patients with type 1 diabetes nephropathy. BMC Med 2009, 4:39-40.
10. Togashi Y, Miyamoto Y. Urinary cystatin C as a biomarker for diabetic nephropathy and its immunohistochemical localization in kidney in Zucker diabetic fatty (ZDF) rats. Exp Toxicol Pathol 2012, 11. [Epub ahead of print].
11. Jeon YK, Kim MR, Huh JE, et al. Cystatin C as an early biomarker of nephropathy in patients with type 2 diabetes. J Korean Med Sci 2011, 26:258-263. 10.3346/jkms.2011.26.2.258, 3031011, 21286018.
12. Weil EJ, Lemley KV, Yee B, et al. Podocyte detachment in type 2 diabetic nephropathy. Am J Nephrol 2011, 33s1:21-24.
13. Dalla Vestra M, Masiero A, Roiter AM, et al. Is podocyte injury relevant in diabetic nephropathy? Studies in patients with type 2 diabetes. Diabetes 2003, 52:1031-1035. 10.2337/diabetes.52.4.1031, 12663476.
14. Nakamura T, Ushiyama C, Suzuki S, et al. Urinary excretion of podocytes in patients with diabetic nephropathy. Nephrol Dial Transplant 2000, 15:1379-1383. 10.1093/ndt/15.9.1379, 10978394.
15. Jim B, Ghanta M, Qipo A, et al. Dysregulated nephrin in diabetic nephropathy of type 2 diabetes: a cross sectional study. PLoS One 2012, 7:e36041. 10.1371/journal.pone.0036041, 3355157, 22615747.
16. Hara M, Yamagata K, Tomino Y, et al. Urinary podocalyxin is an early marker for podocyte injury in patients with diabetes: establishment of a highly sensitive ELISA to detect urinary podocalyxin. Diabetologia 2012, 52:2913-2919.
17. Zheng M, Lv LL, Ni J, et al. Urinary podocyte-associated mRNA profile in various stages of diabetic nephropathy. PLoS One 2011, 6:e20431. 10.1371/journal.pone.0020431, 3105067, 21655212.
18. Sthaneshwar P, Chan SP. Urinary type IV collagen levels in diabetes mellitus. Malays J Pathol 2010, 32:43-47.
19. Kotajima N, Kimura T, Kanda T, et al. Type IV collagen as an early marker for diabetic nephropathy in non-insulindependent diabetes mellitus. J Diabetes Complications 2000, 14:13-17. 10.1016/S1056-8727(00)00064-7, 10925061.
20. Iijima T, Suzuki S, Sekizuka K, et al. Follow-up study on urinary type IV collagen in patients with early stage diabetic nephropathy. J Clin Lab Anal 1998, 12:378-382. 10.1002/(SICI)1098-2825(1998)12:6<378::AID-JCLA8>3.0.CO;2-J, 9850190.
21. Hinokio Y, Suzuki S, Hirai M, et al. Urinary excretion of 8-oxo-7, 8-dihydro-2 deoxyguanosine as a predictor of the development of diabetic nephropathy. Diabetologia 2002, 45:877-882. 10.1007/s00125-002-0831-8, 12107732.
22. Broedbaek K, Weimann A, Stovgaard ES, et al. Urinary 8-oxo-7,8-dihydro-2 deoxyguanosine as a biomarker in type 2 diabetes. Free Radic Biol Med 2011, 51:1473-1479. 10.1016/j.freeradbiomed.2011.07.007, 21820047.
23. Narita T, Hosoba M, Kakei M, et al. Increased urinary excretions of immunoglobulin g, ceruloplasmin, and transferrin predict development of microalbuminuria in patients with type 2 diabetes. Diabetes Care 2006, 29:142-4. 10.2337/diacare.29.01.06.dc05-1063, 16373913.
24. Narita T, Sasaki H, Hosoba M, et al. Parallel increase in urinary excretion rates of immunoglobulin G, ceruloplasmin, transferrin, and orosomucoid in normoalbuminuric type 2 diabetic patients. Diabetes Care 2004, 27:1176-1181. 10.2337/diacare.27.5.1176, 15111541.
25. Qin L-X, Zeng X, Huang G, et al. Changes in serum and urine ceruloplasmin concentrations in type 2 diabetes. Zhong nan da xue xue bao 2004, 29:208-211.
26. Tam FW, Riser BL, Meeran K, et al. Urinary monocyte chemoattractant protein-1 (MCP-1) and connective tissue growth factor (CCN2) as prognostic markers for progression of diabetic nephropathy. Cytokine 2009, 47:37-42. 10.1016/j.cyto.2009.04.001, 19409809.
27. Titan SM, Vieira JM, Dominquez WV, et al. Urinary MCP-1 and RBP: Independent predictors of renal outcome in macroalbuminuric diabetic nephropathy. J Diabetes Complications 2012, 26:546-553. 10.1016/j.jdiacomp, 22981148.
28. Jain S, Rajput A, Kumar Y, et al. Proteomic analysis of urinary protein markers for accurate prediction of diabetic kidney disorder. J Assoc Physicians India 2005, 53:513-520.
29. Otu HH, Can H, Spentzos D, et al. Prediction of diabetic nephropathy using urine proteomic profiling 10 years prior to development of nephropathy. Diabetes Care 2007, 30:638-643. 10.2337/dc06-1656, 17327333.
30. Zürbig P, Jerums G, Hovind P, et al. Urinary Proteomics for Early Diagnosis in Diabetic Nephropathy. Diabetes 2012, 64:3304-3313. [Epub ahead of print].
31. Fu WJ, Xiong SL, Fang YG, et al. Urinary tubular biomarkers in short-term type 2 diabetes mellitus patients: a cross-sectional study. Endocrine 2012, 41:82-88. 10.1007/s12020-011-9509-7, 21779943.
32. Demir K, Abaci A, Küme T, et al. Evaluation of neutrophil gelatinase-associated lipocalin in normoalbuminuric normotensive type 1 diabetic adolescents. J Pediatr Endocrinol Metab 2012, 25:517-523.
33. Alter ML, Kretschmer A, Von W, et al. Early urinary and plasma biomarkers for experimental diabetic nephropathy. Clin Lab 2012, 58:659-671.
34. Lim SC, Liying DQ, Toy WC, et al. Adipocytokine zinc α2 glycoprotein (ZAG) as a novel urinary biomarker for normo-albuminuric diabetic nephropathy. Diabet Med 2012, 29:945-949. 10.1111/j.1464-5491.2011.03564.x, 22211921.
35. Zheng M, Lv LL, Cao YH, et al. Urinary mRNA markers of epithelial-mesenchymal transition correlate with progression of diabetic nephropathy. Clin Endocinol 2012, 76:657-664.
36. McKittrick IB, Bogaert Y, Nadeau K, et al. Urinary matrix metalloproteinase activities: biomarkers for plaque angiogenesis and nephropathy in diabetes. Am J Physiol Renal Physiol 2011, 301:F1326-F1333. 10.1152/ajprenal.00267.2011, 3233865, 21921021.